MarketPulse

GLP-1 weight loss drugs

2 articles
The Motley FoolThe Motley Fool··Jeff Siegel

Hims & Hers Stumbles Post-Earnings Despite Revenue Growth: Margin Squeeze Raises Profitability Concerns

Hims & Hers stock fell 12% after Q1 earnings showed 4% revenue growth to $608.1M but a $92.1M net loss, as GLP-1 margin compression and expansion spending weighed heavily.
NVOHIMSprofitability concernsmargin compression
The Motley FoolThe Motley Fool··Thomas Niel

Viking Therapeutics' VK2735 Could Reshape Weight Loss Market—If Phase 3 Succeeds

Viking Therapeutics' VK2735 could threaten Novo Nordisk and Eli Lilly's GLP-1 dominance if phase 3 trials succeed, triggering potential threefold gains or severe losses.
PFELLYNVOVKTXclinical trialsVK2735